Bicara Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Bicara Therapeutics Inc. (BCAX)
Company Research
Source: Yahoo! Finance
metastatic/unresectable HPV-negative HNSCC, and the program has advanced into the Phase III FORTIFY-HN01 study with 1,500 mg selected as the optimal biological dose and an interim analysis expected mid-2027; the trial is double-blinded and management will not be unblinded. Phase 1b data in ~90 patients showed the 1,500 mg weekly cohort delivered a median duration of response of 21.7 months and median overall survival of 21.3 months , with tumor shrinkage across doses and deeper responses at higher exposure, supporting a loading phase followed by every-three-week maintenance. Bicara completed an oversubscribed public offering that raised $161.8 million net and entered 2026 with $414.8 million in cash and equivalents, enabling increased investment in the pivotal program and pre-launch activities while maintaining runway guidance into the first half of 2029 Interested in Bicara Therapeutics Inc.? Here are five stocks we like better. Bicara Therapeutics (NASDAQ:BCAX) used its inau
Show less
Read more
Impact Snapshot
Event Time:
BCAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAX alerts
High impacting Bicara Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BCAX
News
- A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement [Seeking Alpha]Seeking Alpha
- Bicara Therapeutics (BCAX) had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $16.00. They now have a "neutral" rating on the stock.MarketBeat
BCAX
Earnings
- 3/30/26 - Beat
BCAX
Sec Filings
- 3/31/26 - Form S-8
- 3/30/26 - Form 10-K
- 3/30/26 - Form 8-K
- BCAX's page on the SEC website